Logo

Gene Logic Shares Slide Nearly 15 Percent on News of Goodwill Asset Impairment

Sep 23, 2005

NEW YORK, Sept. 23 (GenomeWeb News) - Shares of Gene Logic's are down 14.8 percent, or $.83, at $4.82 in afternoon trading following news yesterday that the value of the goodwill asset from its 2003 acquisition of TherImmune Research is impaired.

 

The company will announce the amount of the impairment by Nov. 9 after completing its review with a third-party valuation specialist.

Breaking News
The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.